Skip to main content
. 2013 Nov 19;96(10):897–903. doi: 10.1097/TP.0b013e3182a203bd

FIGURE 1.

FIGURE 1

Patient populations and reasons for discontinuation. Patients were excluded from the PPS for major protocol violations; the rate of exclusion ranged from 13.6% to 22.2% across arms. The most commonly reported protocol violation was a deviation of the initial dose of study drug that was either greater than or less than 10% of the recommended dose. Bas, basiliximab; FAS, full anaysis set; PPS, per protocol set; SAF, safety set.